IOSP Quote, Financials, Valuation and Earnings

The Chemours has a net margin of 7.44% compared to Innospec's net margin of -0.29%. Innospec's return on equity of 2.21% beat The Chemours's return on equity of 4.67%.

Innospec has a consensus price target of $122.67, signalling upside risk potential of 37.84%. On the other hand The Chemours has an analysts' consensus of $15.05 which suggests that it could grow by 34.74%. Given that Innospec has higher upside potential than The Chemours, analysts believe Innospec is more attractive than The Chemours.

Innospec has a beta of 1.109, which suggesting that the stock is 10.865% more volatile than S&P 500. In comparison The Chemours has a beta of 1.766, suggesting its more volatile than the S&P 500 by 76.582%.

Innospec has a quarterly dividend of $0.79 per share corresponding to a yield of 1.74%. The Chemours offers a yield of 7.5% to investors and pays a quarterly dividend of $0.09 per share. Innospec pays 108.99% of its earnings as a dividend. The Chemours pays out 172.09% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Innospec quarterly revenues are $440.8M, which are smaller than The Chemours quarterly revenues of $1.4B. Innospec's net income of $32.8M is higher than The Chemours's net income of -$4M. Notably, Innospec's price-to-earnings ratio is 83.95x while The Chemours's PE ratio is 58.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innospec is 1.25x versus 0.29x for The Chemours. Usually stocks with elevated PS ratios are considered overvalued.

Ingevity has a net margin of 7.44% compared to Innospec's net margin of 7.22%. Innospec's return on equity of 2.21% beat Ingevity's return on equity of -118.15%.

Innospec has a consensus price target of $122.67, signalling upside risk potential of 37.84%. On the other hand Ingevity has an analysts' consensus of $51.75 which suggests that it could grow by 20.49%. Given that Innospec has higher upside potential than Ingevity, analysts believe Innospec is more attractive than Ingevity.

Innospec has a beta of 1.109, which suggesting that the stock is 10.865% more volatile than S&P 500. In comparison Ingevity has a beta of 1.305, suggesting its more volatile than the S&P 500 by 30.549%.

Innospec has a quarterly dividend of $0.79 per share corresponding to a yield of 1.74%. Ingevity offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innospec pays 108.99% of its earnings as a dividend. Ingevity pays out -- of its earnings as a dividend.

Innospec quarterly revenues are $440.8M, which are larger than Ingevity quarterly revenues of $284M. Innospec's net income of $32.8M is higher than Ingevity's net income of $20.5M. Notably, Innospec's price-to-earnings ratio is 83.95x while Ingevity's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innospec is 1.25x versus 1.16x for Ingevity. Usually stocks with elevated PS ratios are considered overvalued.

Paramount Gold Nevada has a net margin of 7.44% compared to Innospec's net margin of --. Innospec's return on equity of 2.21% beat Paramount Gold Nevada's return on equity of --.

Innospec has a consensus price target of $122.67, signalling upside risk potential of 37.84%. On the other hand Paramount Gold Nevada has an analysts' consensus of $1.40 which suggests that it could grow by 191.67%. Given that Paramount Gold Nevada has higher upside potential than Innospec, analysts believe Paramount Gold Nevada is more attractive than Innospec.

Innospec has a beta of 1.109, which suggesting that the stock is 10.865% more volatile than S&P 500. In comparison Paramount Gold Nevada has a beta of 1.017, suggesting its more volatile than the S&P 500 by 1.74%.

Innospec has a quarterly dividend of $0.79 per share corresponding to a yield of 1.74%. Paramount Gold Nevada offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innospec pays 108.99% of its earnings as a dividend. Paramount Gold Nevada pays out -- of its earnings as a dividend.

Innospec quarterly revenues are $440.8M, which are larger than Paramount Gold Nevada quarterly revenues of --. Innospec's net income of $32.8M is higher than Paramount Gold Nevada's net income of -$2.6M. Notably, Innospec's price-to-earnings ratio is 83.95x while Paramount Gold Nevada's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innospec is 1.25x versus -- for Paramount Gold Nevada. Usually stocks with elevated PS ratios are considered overvalued.

Solitario Resources has a net margin of 7.44% compared to Innospec's net margin of --. Innospec's return on equity of 2.21% beat Solitario Resources's return on equity of --.

Innospec has a consensus price target of $122.67, signalling upside risk potential of 37.84%. On the other hand Solitario Resources has an analysts' consensus of $1.50 which suggests that it could grow by 150.42%. Given that Solitario Resources has higher upside potential than Innospec, analysts believe Solitario Resources is more attractive than Innospec.

Innospec has a beta of 1.109, which suggesting that the stock is 10.865% more volatile than S&P 500. In comparison Solitario Resources has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.16%.

Innospec has a quarterly dividend of $0.79 per share corresponding to a yield of 1.74%. Solitario Resources offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innospec pays 108.99% of its earnings as a dividend. Solitario Resources pays out -- of its earnings as a dividend.

Innospec quarterly revenues are $440.8M, which are larger than Solitario Resources quarterly revenues of --. Innospec's net income of $32.8M is higher than Solitario Resources's net income of -$511K. Notably, Innospec's price-to-earnings ratio is 83.95x while Solitario Resources's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innospec is 1.25x versus -- for Solitario Resources. Usually stocks with elevated PS ratios are considered overvalued.